Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Pyridoxal phosphate as an antisickling agent in vitro.
J A Kark, … , P G Tarassoff, R Bongiovanni
J A Kark, … , P G Tarassoff, R Bongiovanni
Published May 1, 1983
Citation Information: J Clin Invest. 1983;71(5):1224-1229. https://doi.org/10.1172/JCI110871.
View: Text | PDF
Research Article

Pyridoxal phosphate as an antisickling agent in vitro.

  • Text
  • PDF
Abstract

Although pyridoxal phosphate is known to inhibit gelation of purified hemoglobin S, antisickling activity has never been demonstrated for intact erythrocytes. We incubated washed erythrocytes at 37 degrees C either in buffer alone, or with added pyridoxal phosphate or pyridoxal, washed these cells, suspended them in untreated buffer, and compared the percent modified hemoglobin, the oxygen affinity, and the extent of sickling under hypoxia. Pyridoxal phosphate modified intracellular hemoglobin more slowly than pyridoxal. Pyridoxal phosphate lowered the oxygen affinity of normal cells, but had no effect on oxygen binding by sickle cells. Pyridoxal increased the oxygen affinity of normal and sickle erythrocytes equally. Pyridoxal phosphate significantly inhibited sickling of sickle or sickle trait erythrocytes (P less than 0.001). Inhibition of sickling by pyridoxal phosphate was largely independent of oxygen binding; whereas inhibition of sickling by pyridoxal was almost entirely dependent on increased oxygen binding. Although pyridoxal phosphate and pyridoxal both inhibit sickling by modification of hemoglobin S, they differ in the kinetics of whole cell modification, the effect on oxygen affinity of intact cells, and the mechanism of action of the antisickling activity.

Authors

J A Kark, P G Tarassoff, R Bongiovanni

×

Total citations by year

Year: 2021 2016 2002 2000 1990 1987 Total
Citations: 1 1 1 1 1 1 6
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (6)

Title and authors Publication Year
FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice
A Shrestha, M Chi, K Wagner, A Malik, J Korpik, A Drake, K Fulzele, S Guichard, P Malik
Blood Advances 2021
Nutrient Insufficiencies/Deficiencies in Children With Sickle Cell Disease and Its Association With Increased Disease Severity: Nutrition Deficiencies in Childhood Sickle Cell Disease
DJ Martyres, A Vijenthira, N Barrowman, S Harris-Janz, C Chretien, RJ Klaassen
Pediatric Blood & Cancer 2016
Vitamin B6 Status of Children With Sickle Cell Disease
MC Nelson, BS Zemel, DA Kawchak, EM Barden, EA Frongillo, SP Coburn, K Ohene-Frempong, VA Stallings
Journal of Pediatric Hematology/Oncology 2002
Reactive Species in Sickle Cell Disease
M Aslan, D Thornley-Brown, BA Freeman
Annals of the New York Academy of Sciences 2000
Antisickling Properties of Pyridoxine Derivatives
CL Natta, J Kurantsin-Mills, P Garry, KL Hodge
Annals of the New York Academy of Sciences 1990
Nutrition and sickle cell disease
JD Reed, R Redding-Lallinger, EP Orringer
American Journal of Hematology 1987

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts